Matching articles for "rhinosinusitis"
Warning: Undefined variable $out in /var/www/html/wp-content/plugins/tml/relatedterm.php on line 30
Warning: Undefined property: stdClass::$url in /var/www/html/wp-content/plugins/tml/relatedterm.php on line 41
In Brief: Dupilumab (Dupixent) for Allergic Fungal Rhinosinusitis
The Medical Letter on Drugs and Therapeutics • June 22, 2026; (Issue 1757)
Dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously
injected interleukin (IL)-4 receptor alpha antagonist that is FDA-approved
for several indications, including treatment of chronic
rhinosinusitis...
Dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously
injected interleukin (IL)-4 receptor alpha antagonist that is FDA-approved
for several indications, including treatment of chronic
rhinosinusitis with nasal polyps, has now been approved for
treatment of allergic fungal rhinosinusitis (AFRS) in patients
≥6 years old who previously had sinonasal surgery. It is the
first drug to be approved in the US for this indication.